Cellular and molecular dysregulation of the esophageal epithelium in systemic

sclerosis

Matthew Dapas[1,2], Margarette H. Clevenger[3], Hadijat M. Makinde[1,2], Tyler Therron[1], Dustin A.

Carlson[3,4], Mary Carns[1], Kathleen Aren[1], Cenfu Wei[3], Lutfiyya N. Muhammad[5], Carrie L.

Richardson[1], Parambir S. Dulai[2,3], Monique Hinchcliff[6], John E. Pandolfino[3,4], Harris R.

Perlman[1,2*], Deborah R. Winter[1,2*], Marie-Pier Tetreault[2,3*]

Affiliations:

1.   Division of Rheumatology, Department of Medicine, Northwestern University Feinberg School of

Medicine, Chicago, IL, USA

2.   Center for Human Immunobiology, Northwestern University Feinberg School of Medicine, Chicago,

IL, USA

3.   Division of Gastroenterology & Hepatology, Department of Medicine, Northwestern University

Feinberg School of Medicine, Chicago, IL, USA

4.   Kenneth C. Griffin Esophageal Center of Northwestern Medicine, Northwestern University Feinberg

School of Medicine, Chicago, IL, USA

5.   Department of Preventive Medicine, Northwestern University Feinberg School of Medicine, Chicago,

IL, USA

6.   Section of Rheumatology, Allergy & Immunology, Department of Medicine, Yale School of

Medicine, New Haven, CT, USA

*These authors jointly supervised the work

ABSTRACT

Systemic sclerosis (SSc) is a rare autoimmune disease characterized by vasculopathy and fibrosis of the skin and internal organs. Individuals with SSc often suffer from chronic acid reflux and dysphagia due to loss of esophageal motility. However, the pathogenesis of esophageal dysmotility in SSc is poorly understood. To determine whether distinct changes in esophageal epithelial cells contribute to impaired motility in SSc, we investigated the stratified squamous esophageal epithelium from proximal and distal biopsies using single-cell RNA sequencing (n=306,372 cells) in individuals with SSc compared those with gastroesophageal reflux disease (GERD) as well as healthy controls. The proportion of epithelial cells in the apical, superficial compartment of the esophageal epithelium was significantly reduced in SSc (9.4% vs 21.6% in HCs). Differential gene expression in SSc was primarily limited to the superficial compartment (3,572 genes vs. 232 in all other compartments, based on pseudobulk analysis), with significant upregulation of extracellular matrix and keratinization genes. These cellular and molecular changes in SSc were highly correlated with those seen in GERD, indicating they were secondary to reflux; however, their magnitudes were more pronounced in the proximal esophagus, suggesting that esophageal dysmotility leads to greater proximal acid exposure, which may contribute to aspiration. SSc-specific gene dysregulation implicated immunoregulatory pathways likely pertinent to pathogenic mechanisms. Cell type localization and SSc-specific changes were confirmed by spatial molecular imaging. By offering a comprehensive view of transcriptional dysregulation at single-cell resolution in human esophageal epithelial cells in SSc compared to GERD and healthy tissue, this work clarifies the state of epithelial cells in SSc-induced esophageal dysfunction.

INTRODUCTION

Systemic sclerosis (SSc), also known as scleroderma, is an immune-mediated rheumatic disease of unknown etiology that causes fibrosis of the skin and internal organs. Although uncommon (18-26 per 100,000 people)[1-4], SSc is one of the deadliest autoimmune disorders[5], with a 10-year survival rate of 45-68% following diagnosis[4,6,7]. Over 90% of individuals with SSc report gastrointestinal dysfunction[8], with esophageal dysmotility being the most common gastrointestinal manifestation[9]. Individuals with SSc and esophageal involvement typically suffer from chronic acid reflux and dysphagia due to loss of esophageal motility and are at much greater risk of esophageal stricture and Barrett's esophagus[8,10,11]. The prevalence of esophageal involvement was nearly twice as high in individuals with SSc who died within 5 years of disease diagnosis[12].

There are multiple, interrelated mechanisms that may cause esophageal dysmotility in SSc. Vascular damage and/or neurogenic impairment can lead to smooth muscle atrophy[13], which is the predominant esophageal pathology in autopsies of patients with SSc[14]. Inflammatory signatures[15], absence of anti-centromere antibodies[16], and presence of anti-topoisomerase I antibodies are associated with esophageal pathologies, as well[8]. Complicating research efforts is significant clinical and molecular heterogeneity observed between SSc patients[17-19] and difficulty distinguishing between effects from autoimmune processes and secondary factors such as severe gastroesophageal reflux disease (GERD). Consequently, the pathogenesis of esophageal disease in SSc remains poorly understood.

Functional investigations of SSc esophageal involvement have primarily focused on peristalsis or contractions of the muscularis propria[20]. However, the mucosa is no less essential for normal esophageal transport[21,22], and recent studies have suggested that esophageal epithelial cells (EECs) may play a more central role in the pathogenesis of SSc esophageal involvement than previously thought[23]. Mouse models with epithelial-cell-specific knockout of *Fli1*, an Ets transcription factor implicated in SSc pathogenesis[24], spontaneously develop dermal and esophageal fibrosis and interstitial lung disease[25]. Importantly, the resultant lung disease is mediated by T-cell autoimmunity, but fibrosis of the skin and esophagus persist in

mice additionally lacking mature T and B cells, suggesting that the fibrosis is principally driven by the

epithelia[23,25].

Most studies implicating epithelial cells in SSc esophageal dysmotility have been performed in

mice or *in vitro*, and molecular analyses in humans have so far been limited to bulk tissues[15]. Furthermore,

single-cell gene expression studies performed in other diseases of the esophagus, including squamous cell

carcinoma[26,27] and allergic eosinophilic esophagitis[28,29], have identified substantial cellular and molecular

changes in EECs compared to healthy tissue, such as significant expansion of non-proliferative suprabasal

cells[28,29]. Therefore, to comprehensively investigate the effects of SSc on the esophageal epithelium, we

performed single-cell RNA sequencing (scRNA-seq) of esophageal mucosal biopsies from SSc patients

with clinically significant esophageal involvement and compared EEC distributions and gene expression

signatures to non-SSc individuals with GERD and healthy controls (HCs). We further validated cell type

localization and SSc effects using spatial molecular imaging from independent SSc and HC samples. By

examining gene expression profiles from human tissue at single-cell resolution, this work sheds essential

light on the cellular roots of esophageal dysfunction in SSc by clarifying the pathogenic role of the

squamous epithelium, one of the most integral tissues supporting healthy esophageal function.

METHODS

Subjects

The study protocol received approval from the Northwestern University Institutional Review Board. The

SSc study population were recruited from adult patients aged 18 to 89 diagnosed with SSc according to the

2013 ACR/EULAR Classification Criteria, who visited the Northwestern Medicine Esophageal Center

between 2020 and 2021for esophageal symptom evaluation and motility testing, as described previously[20].

Patients with non-SSc GERD were recruited at the first clinic visit following positive wireless pH testing[29].

Patients with technically inadequate panometry or manometry studies, previous foregut surgeries (including

prior pneumatic dilation), candida esophagitis, history of esophageal cancer, or mechanical obstructions in

the esophagus such as esophageal stricture, eosinophilic esophagitis, severe reflux esophagitis (Los Angeles

classification C or D), or hiatal hernias larger than 5 cm were excluded. HCs met asymptomatic criteria

including lack of esophageal symptoms, no history of alcohol dependency or tobacco use, body mass index

less than 30kg/m^2, and no current antacid or proton pump inhibitor treatment[29]. The study protocol received

approval from the Northwestern University Institutional Review Board.

Symptom evaluation and motility testing

Esophageal function testing included functional lumen imaging probe (FLIP) panometry during sedated

endoscopy, high-resolution manometry (HRM), and in some subjects, 24-hour pH-impedance or timed-

barium esophagogram, which were completed and interpreted as previously described[30-33]. HRM

classifications were based on the application of the Chicago Classification v4.0 to 10 supine and 5 upright

test swallows[33]. FLIP panometry classifications were based on previous evaluation of asymptomatic

volunteers and patients[34-36]. During endoscopy (same encounter as FLIP), esophageal mucosal biopsies

were obtained at approximately 5-cm ("distal esophagus") and 15-cm ("proximal esophagus") proximal to

the squamocolumnar junction using Boston Scientific Radial Jaw 4 standard capacity forceps. Acid

exposure was measured as the percentage of time with esophageal pH<4 over a monitoring period of 24

hours. Most patients also completed validated symptom-questionnaires (patient-reported outcome

measures) on the day of esophageal motility testing with FLIP or HRM, including the Brief Esophageal

Dysphagia Questionnaire (BEDQ), the Gastroesophageal Reflux Disease Questionnaire (GerdQ), and the

Northwestern esophageal quality of life (NEQOL) survey.[37-39] SSc disease duration was measured from

onset of the first non-Raynaud symptom.

Single-cell RNA-sequencing sample processing and sequencing

Esophageal mucosal biopsies from proximal and distal esophagus were processed for scRNA-seq as

described in Clevenger et al[29]. Briefly, following tissue digestion and filtering, cell suspensions met 85%

minimum viability via Cellometer Auto2000 (Nexcelom Bioscience). Cells were loaded into a Chromium

iX controller (10X Genomics) on a Chromium Next GEM Chip G (10X Genomics) to capture

approximately 10,000 cells per sample and were processed for encapsulation following the manufacturer's

protocol. Cell barcoding and library construction were performed using the 10X Genomics Chromium Next

GEM Single Cell 3' Reagents Kits v3.1 and Dual Index Kit TT Set A according to the manufacturer's

protocol. Sequencing was performed by the NUSeq Core using the Illumina NovaSeq 6000. Paired-end

reads consisting of a 28-base-pair read for cell barcodes and unique molecular identifiers and a 90-base-

pair read for transcripts were aligned to the GRCh38 reference transcriptome using Cell Ranger v6.1.2.

Single-cell sample and cell quality control

Samples with high ambient RNA (<70% of sequencing reads mapped to cells) were removed from

consideration. Gene expression counts generated by Cell Ranger were analyzed using Seurat v4.3.0[40] in R

v4.3.0. Cells with low gene diversity (<200 unique genes), low unique molecular identifier counts (<500),

or excessive counts (>100,000) were removed from consideration. Cells with high proportions of

mitochondrial DNA reads, indicative of apoptosis or lysis, were removed using the bivariate regression

models implemented in the miQC package[41]. Cells were filtered if their proportion of reads mapped to

mitochondrial DNA exceeded 0.05 and their posterior probability of belonging to a compromised cell

distribution was greater than 0.75 according to miQC. Doublets, in which more than one cell is clumped

together in a single droplet, were predicted and removed using scDblFinder[42] with an expected, additive

doublet rate of 0.01 per thousand cells with standard deviation of 0.01.

Sample integration and cell type annotation

Individual scRNA-seq expression profiles were normalized and integrated on 3,000 variable features using

Seurat's SCTransform procedure[43] with v2 regularization[44] and canonical correlation analysis dimension

reduction. Integration anchors were determined using a reference consisting of three pairs of proximal and

distal samples from HCs. Principal component (PC) analysis was performed on the transformed and

integrated expression counts. Uniform manifold approximation and projection (UMAP)[45] embeddings were

calculated on the top 40 PCs with n=200 neighbors. Cell clustering was performed using Seurat's

modularity-based clustering on a shared nearest neighbor (SNN) graph with k=25 on the top 40 PCs.

Clusters were annotated according to the expression of established cell-specific gene markers

(**Supplemental Figure 1**). For annotation of smaller cell clusters, we first filtered out the epithelial,

myeloid, lymphoid, and endothelial cell clusters and then recomputed PCs and re-clustered the subset (PCs

= 25, k=15).

Epithelial cell characterization

After isolating the subset of epithelial cell clusters, we further filtered cells with disproportionately low

read counts (≤3,500; **Supplemental Figure 2, A-E**). The samples were then re-integrated using the

procedure described above. UMAP embeddings were calculated on the top 35 PCs with n=100 neighbors.

Epithelial compartments (basal, proliferating basal, proliferating suprabasal, suprabasal, and superficial)

were identified according to expression of established compartment-specific and cell cycle markers

(**Supplemental Figure 2F**)[28,29,46-48]. For the basal, suprabasal, and superficial compartments, we computed

composite gene signature scores using Seurat's AddModuleScore() function (**Supplemental Figure 2G**).

Cells were initially clustered on an SNN graph with k=50 with resolution=0.25 (**Supplemental Figure**

2H), but because the modularity optimization clustering implemented in Seurat grouped proliferating cells

across different epithelial compartments and inconsistently distinguished suprabasal and superficial cells,

we applied K-means clustering on the expression of the compartment-specific markers (**Supplemental**

Figure 2F). We performed separate K=2 K-means clustering on 1) the Seurat clusters containing basal and

early suprabasal cells (clusters 1-5) to distinguish basal from suprabasal compartments and 2) the Seurat

clusters containing late suprabasal and superficial cells (clusters 6-8) to demarcate suprabasal and

superficial compartments (**Supplemental Figure 2, I-J**). Proliferating epithelial cells were identified using

Seurat's CellCycleScoring() function. Cells predicted as being in S or G2/M phases based on the relative

expression of corresponding markers[49] were labeled as proliferating cells (**Supplemental Figure 2K**). We

tested for statistical differences in proportions of epithelial cell populations between sample groups using

MASC[50].

Gene expression analysis

To identify dysregulated pathways in SSc, we first calculated differential gene expression between

conditions (SSc, non-SSc GERD, HCs) within each epithelial compartment, considering each cell as a

sample. Differential gene expression was calculated using the FindMarkers() function in Seurat with the

Wilcoxon rank-sum test on log-normalized RNA counts for genes expressed in at least 1% of cells by

compartment. We adjusted for multiple testing using a Bonferroni correction accounting for the number of

genes tested. Genes with an adjusted P<0.05 and absolute $\log_2$ fold change >0.1 were considered

significantly differentially expressed. [51,52] Genes were then ranked by the magnitude and statistical certainty

of their expression differences:

188
$$Weight = -\log_{10}(p) * abs(\log_2[FC])$$

Gene set enrichment was calculated using 3,795 canonical pathway gene sets from the Human Molecular

Signatures Database[53] using gene set enrichment analysis (GSEA)[51,52]. Statistical gene set enrichment was

calculated using one-way positive enrichment with 100,000 permutations on pathways with at least 10

genes. Mitochondrial and ribosomal genes were excluded from the GSEA.

For pseudobulk differential expression analysis we aggregated RNA counts per sample within

epithelial compartments. Genes with at least one count per million detected in at least 75% of samples in at

least one condition per epithelial compartment were analyzed. To mitigate outlier-driven signals, genes

with log-transformed expression greater than 3 standard deviations from the mean in exactly one individual

were excluded. Differential gene expression was evaluated using edgeR v3.42.4[54-56]. Gene expression was

modeled using a quasi-likelihood negative binomial generalized linear model, with global negative-

binomial trended dispersion estimated across all samples and gene-specific quasi-likelihood dispersions

estimated within each epithelial compartment. Differences in gene expression across conditions were

assessed using quasi-likelihood F-tests with false-discovery rate (FDR) adjustment. Differences in the

proportions of genes that were significantly differentially expressed between groups were assessed using a

chi-square test. Differences in gene expression profiles between biopsy locations were determined by

measuring intra-individual correlations for the 2,000 most variable genes at the single-cell level aggregated

by sample, epithelial compartment, and biopsy location.

Transcription factor enrichment analyses were conducted on the pseudobulk results using the

enricher() function from clusterProfiler v4.8.3[57]. We used consensus results from ENCODE[58] and ChEA[59],

as curated by the Ma'ayan Lab[60] and available at http://amp.pharm.mssm.edu/Enrichr/[61]to test for the

enrichment of transcription factor target genes from among genes that were differentially expressed

between SSc, GERD, and HCs with Bonferroni-adjusted $p<0.05$. Background gene sets were comprised of

the genes included in the pseudobulk differential expression analyses for each epithelial compartment.

Transcription factors absent from the background gene set were removed as candidate transcription factors.

Separate enrichment tests were performed for all differentially expressed genes and those that were

upregulated or downregulated in SSc. Enrichment results were adjusted using a Bonferroni correction

accounting for the number of transcription factors with more than 2 genes that were significantly

differentially expressed.

Pseudobulk sample permutation

Because of the sample size imbalance by disease state, which inherently yields different statistical power

for different tests across conditions, we permuted differential expression testing with equivalent sample

sizes to better evaluate the relative extent of dysregulation by EEC compartment and biopsy location

between SSc and GERD. We permuted all possible combinations of SSc samples with sample size n=4 for

both the proximal and distal regions and used the median statistics in the SSc vs. HC tests to more directly

compare the results with those observed in GERD vs. HCs.

Spatial imaging sample preparation

Tissue sections were mounted on Leica Biosystems Apex BOND Superior Adhesive Slides (cat# 3800040) and subsequently baked overnight at 60 °C, followed by preparation for in-situ hybridization (ISH) by deparaffinization in CitriSolv (2x 5min), 100% ethanol (2x 5min) and heat-induced epitope retrieval (HIER) at 100 °C for 15 min using low pH citrate buffer (NanoString/Bruker). After HIER, tissue sections were digested with Proteinase K (2 µg/ml) diluted in PBS at 40 °C for 30 min. Tissue sections were then washed twice with diethyl pyrocarbonate (DEPC)-treated water (DEPC H2O) and incubated in 0.0015% fiducials (NanoString/Bruker) in 2X saline sodium citrate, 0.001% Tween-20 (SSCT solution) for 5 min at room temperature in the dark. Excess fiducials were rinsed from the slides with 1X PBS, then tissue sections were fixed with 10% neutral buffered formalin (NBF) for 5 min at room temperature. Fixed samples were rinsed twice with Tris-glycine buffer (0.1 M glycine, 0.1 M Tris-base in DEPC H2O) and once with 1X PBS for 5 min each before blocking with 100 mM N-succinimidyl (acetylthio)acetate (NHS-acetate, Thermo Fisher Scientific) in NHS-acetate buffer (0.1 M NaP, 0.1% Tween pH 8 in DEPC H2O) for 15 min at room temperature. The sections were then rinsed with 2X saline sodium citrate (SSC) for 5 min and an Adhesive Hybridization Chamber (NanoString/Bruker) was placed over the tissue. ISH probes were prepared by incubation at 95 °C for 2 min and submerged in ice, and the ISH probe mix was pipetted into the hybridization chamber. The chamber was sealed to prevent evaporation, and hybridization was performed at 37 °C for 18 hrs. Tissue sections were washed twice in 50% formamide (Ambion) in 2X SSC at 37 °C for 25 min, washed twice with 2X SSC for 2 min at room temperature, and blocked with 100 mM NHS-acetate in the dark for 15 min. In preparation for loading onto the spatial imaging instrument, a flow cell was affixed to the slide.

Spatial molecular imaging and data processing

Single-cell spatial transcriptomic analysis was performed using the CosMx Spatial Molecular Imager (NanoString/Bruker), featuring the 6k Human Discovery Panel gene list, which consists of 6,175 RNA targets designed to provide coverage across all major biological pathways. Spatial fields of view (FOVs)

with average counts per cell <100 were removed from consideration. Cells with low RNA counts (<20),

high proportions of counts from negative probes (>0.1), extreme size (p<0.01 by Grubb's test), or more

detected genes than counts were removed. Gene probes with expression levels below median background

noise, as determined by negative probe detection, were also removed. Counts were log normalized using

Seurat[40]. Cell segmentation errors were predicted using scDblFinder[42]. To annotate the cells, we performed

label transfer from the single-cell dataset with SingleR[62] using default parameters on the intersect of

quantified genes. Gene expression differences between groups in the spatial data were evaluated using

Wilcoxon rank-sum tests.

Clinical phenotype associations

To test for associations with categorical measures of esophageal function (FLIP, HRM, and a combined

FLIP and HRM with neuromyogenic [NM] classification[63]), we performed ordinal logistic regression that

modeled likelihoods of increasing clinical severity. For this analysis, we excluded SSc patients with

achalasia or esophagogastric junction outflow obstruction (EGJOO). For FLIP we combined the

"borderline/diminished" and "impaired/disordered" phenotypes. For NM we combined the Stage I and

Stage II ineffective motility phenotypes. The resultant ordering for the ordinal regression was "normal" <

"ineffective" < "absent" for HRM; "normal" < "borderline/diminished & impaired/disordered" < "absent"

for FLIP; and "normal" < "stages I & II – ineffective" < "stage III – absent" for NM.

For association testing with quantitative clinical measures in SSc, we first performed a principal

components analysis (PCA) on a set of nine quantitative clinical traits: HRM mean distal contractile interval

(DCI), HRM basal esophagogastric junction (EGJ) pressure, HRM EGJ contractile index, HRM median

integrated relaxation pressure (IRP), FLIP intra-balloon pressure at 60ml, FLIP EGJ distensibility index,

the GerdQ impact score, the BEDQ score, and the NEQOL score. Missing values were imputed with the

mean across all patients. We then modeled associations with the first two PCs using linear regression. Gene

expression was represented using log-transformed counts.

RESULTS

Whole tissue scRNA-seq was performed on paired proximal and distal mucosal biopsies from ten patients with SSc, four non-SSc patients with GERD, and six HCs. All participants but one in each group were female (**Table 1**). SSc patients were significantly older than HCs (54.9 vs 27.0 years; P<0.001). Among SSc patients, six had the limited cutaneous subtype, three had the diffuse cutaneous subtype, and one had sine scleroderma with no cutaneous symptoms (**Supplemental Table 1**). Mean SSc disease duration at the time of biopsy was 132 months. All SSc patients had positive serum antinuclear antibodies and impaired esophageal motility. Following sample-level quality control (**Supplemental Table 2**), 39 samples were retained for analysis, including 19 from the proximal esophagus and 20 from the distal esophagus. Four additional sets of proximal and distal biopsies were collected for spatial molecular imaging from two SSc patients with diminished esophageal contractility and two healthy controls (**Supplemental Table 3**).

Characterization of esophageal mucosal cell populations

A total of 306,372 esophageal cells (7,856 mean cells per sample) were retained for cell clustering and gene expression analysis. Each cell type was identified according to the expression of established cell-specific gene markers including *KRT6A, KRT13,* and *KRT15* for epithelial cells (**Figure 1, A-D; Supplemental Table 4**; **Supplemental Figure 1**). Epithelial cells comprised the bulk of the sample (n=264,858; 86.45%), followed by lymphoid cells (n=25,129; 8.20%), myeloid cells (n=10,019; 3.27%), endothelial cells (n=4,027; 1.31%), and all other cell types (n=2,339; 0.76%). We observed heterogeneity in non-epithelial cell type proportions by condition and biopsy location (**Figure 1E**) but focused on the epithelium for the remainder of the study.

Significant loss of superficial EECs in SSc

Following isolation of the epithelial cell cluster and additional quality control (**Supplemental Figure 2, A-E**), we characterized the remaining 230,720 EECs according to their differentiation and cell cycling states

(**Figure 2A**). We classified the EECs into five primary compartments: basal (n=55,818; 24%), proliferating

basal (n=36,439; 16%), proliferating suprabasal (n=25,314; 11%), suprabasal (n=82,283; 36%), and

superficial (n=30,866; 13%) based on relative expression of canonical epithelial genes and cell cycle

markers (**Figure 2, B-C; Supplemental Figure 2, F-K**). Spatial localization of the annotated single-cell

clusters was confirmed using spatial molecular imaging (**Figure 2D, Supplemental Figure 3**). Roughly

40% of basal cells and 24% of suprabasal cells were proliferating, and the fractions of cells that were

proliferating did not differ by disease (**Figure 2E**). Proportions of basal and suprabasal cells were not

significantly different across conditions, but there were significantly fewer proximal superficial cells in SSc

compared to HCs (μ_{SSc}=0.10, μ_{HC}=0.21, P=0.003, **Figure 2E**).

EEC gene dysregulation predominantly in superficial cells, highly correlated in SSc and GERD

Most differentially expressed genes (DEGs) were only differentially expressed in one epithelial

compartment (**Supplemental Figure 4A**), and differential gene expression between conditions was most

pronounced in superficial EECs (**Figure 3A**). At the single-cell level, 674 and 434 genes were significantly

differentially expressed between SSc and HCs in the superficial compartment in the proximal and distal

regions, respectively, compared to 171 proximal and 157 distal non-proliferating basal DEGs and 172

proximal and 377 distal non-proliferating suprabasal DEGs (**Supplemental Tables 5-6**). To more robustly

characterize gene expression differences between conditions[64], we performed pseudobulk differential

expression analysis by aggregating single-cell RNA counts per sample within EEC compartments. Overall,

pseudobulk gene expression patterns clustered by compartment rather than by condition or biopsy location

(**Supplemental Figure 4B**). Significant differences in gene expression between conditions were largely

limited to superficial cells, suggesting that the apical cell layers of the esophageal epithelium are most

affected by SSc (**Supplemental Figure 4, C-D**). There were 3,572 genes differentially expressed between

SSc and HCs with FDR q<0.05 in the superficial compartment, compared to just 232 total in all other

compartments (**Supplemental Table 7**).

The differential expression observed in SSc was strongly correlated with the changes seen in

GERD, with many of the same genes significantly dysregulated in both SSc and GERD compared to HCs.

Overall correlations in pseudobulk $\log_2$ fold change between SSc vs. HCs and GERD vs. HCs were

consistently strong, ranging between r=0.51-0.62 across EEC compartments (**Supplemental Table 7**).

Depending on the compartment and biopsy location, 22-44% of single-cell DEGs in SSc or GERD were

differentially expressed in both conditions (**Figure 3A**; **Supplemental Table 5**). Consequently, the single-

cell DEGs in SSc and GERD were significantly enriched for some of the same pathways, particularly those

related to the extracellular matrix and keratinization (**Figure 3B**). These included matrisome (suprabasal,

distal; superficial, distal) and matrisome-associated genes (suprabasal, distal); cornified envelope formation

(suprabasal, distal; superficial, distal), and keratinization genes (suprabasal, distal; superficial, distal);

developmental biology-related genes (suprabasal, distal; superficial, distal). The leading edges of these

significant pathways, which comprised the genes driving their enrichment, included shared protein families,

including serine protease inhibitors (serpins), keratins, small proline-rich proteins (SPRRs) and S100

proteins (**Supplemental Table 8**). Among the most enriched pathways specific to SSc were those related

to the regulation of metal and immune homeostasis. In particular, innate immune system genes were

uniquely enriched in SSc compared to HCs in superficial EECs of the proximal esophagus.

Overall gene expression levels were highly similar between esophageal biopsy locations, with mean

intra-individual correlations grouped by condition and epithelial compartment ranging from r=0.95 to

r=0.99 for the 2,000 most variable genes (**Figure 3C**; **Supplemental Table 9**). However, we did observe

some notable differences in differential gene expression patterns by biopsy location. For example, single-

cell differential expression in the suprabasal compartment was significantly greater in the distal esophagus

than in the proximal esophagus for both SSc (172 proximal vs. 377 distal, $p=2.5\times10^{-20}$) and GERD (159

proximal vs. 434 distal, $p=1.1\times10^{-32}$; **Figure 3A; Supplemental Figure 4A**). Furthermore, at the single-

cell level, there were more unique DEGs in SSc vs. HCs in the proximal esophagus (897 proximal vs. 806

distal, $p=7.0\times10^{-2}$), but the opposite was true in GERD vs. HCs (910 proximal vs. 1,075 distal, $p=1.6\times10^{-5}$;

Figure 3A). Similarly, within the superficial compartment, where most differential expression was

observed, GERD exhibited greater relative changes in pseudobulk gene expression in the distal esophagus

than in the proximal region, as indicated by the decreased slope between fold-changes (m=0.44 vs. 0.87;

Figure 3D; Supplemental Table 10). The superficial compartment also featured the greatest range and

lowest overall values of intra-individual gene expression correlations between biopsy locations, particularly

in SSc (**Figure 3C**). These differences by biopsy location suggest that the relative disease effect on the

proximal esophagus compared to the distal esophagus is greater within SSc than within GERD.

More genes were significantly differentially expressed in SSc than in GERD in the pseudobulk

analysis, but in terms of relative fold change vs. HCs, we observed greater expression changes in GERD

(**Figure 3D**). To determine whether the greater number of SSc samples were driving this discrepancy, we

performed all possible sample permutations with equal numbers of SSc and GERD samples (n=4) and

repeated differential gene expression testing to more directly compare the relative number of DEGs in both

conditions. In superficial cells from the proximal esophagus, there were more DEGs in SSc in 60% of

permutations, but the relative FC differences were greater in GERD in 61% of permutations (**Supplemental**

Figure 4, E-F; Supplemental Table 11). In the distal region, there were more DEGs in GERD in 62% of

permutations, and the relative FC differences were greater in GERD in all permutations. The correlations

between SSc and GERD in terms of relative gene expression changes were consistently much higher in the

proximal region permutations than in the distal region (**Supplemental Figure 4G**). The permutation results

confirmed that the differences in gene expression observed in SSc relative to GERD were not simply due

to differences in sample size. In summary, the superficial epithelium is most altered in SSc, exhibiting

similar transcriptional changes to GERD, but with relatively greater effect in the proximal esophagus

compared with distal.

SSc-specific gene dysregulation points to immunoregulatory pathways

Among the most upregulated SSc-specific genes (**Figure 3D; Supplemental Figure 4H**) were genes

related to inflammation (*PTGES*, *MFGE8*)[65,66], innate immune response (*FCGBP, BST2, CD44,*

APOBEC3A)[67-70], immune cell migration (*C10orf99*, *LTB4R*, *ACKR3*)[71-73], antigen presentation (*HLA-B*,

CD74, *TAP1*, *PSMB8*, *PSMB9*)[74], natural killer cell activation (*CLEC2B*)[75], and fibroproliferation (*SGK1*,

HBEGF)[76,77]. Four of the top five and eight of the top 20 most downregulated SSc-specific genes by fold

change in superficial EECs in the proximal esophagus were metallothioneins (*MT1A*, *MT1E*, *MT1F*, *MT1G*,

MT1H, *MT1M*, *MT1X*, *MT2A*). The metallothioneins comprised the bulk of three pathways uniquely

enriched in SSc with P<0.001: zinc homeostasis, copper homeostasis, and cellular responses to stimuli

(**Figure 3B**). The most down-regulated SSc-specific gene across both the proximal and distal esophagus

was the *H19* lncRNA. Interestingly, the most down-regulated gene by fold change in GERD, *MUC22*, was

not differentially expressed in SSc. One gene, *SLC8A1-AS1*, was significantly differentially expressed in

both GERD and SSc, but in opposite directions (**Figure 3D; Supplemental Figure 4H; Supplemental**

Table 10).

Transcription factors enriched in proximal SSc esophagus

We next examined whether DEGs in SSc superficial cells were significantly enriched for targets of specific

transcription factors. Among genes differentially expressed in SSc compared to GERD, the target genes of

IRF1 were significantly enriched (**Supplemental Table 12**). IRF1 targets were significantly enriched

among all proximal superficial DEGs (p_{adj}=0.021) and among only those that were downregulated

(p_{adj}=0.0024). However, *IRF1* was not itself differentially expressed in superficial cells in SSc compared to

GERD. Compared to HCs, three transcription factors were significantly enriched in SSc in the proximal

esophagus, including MYC (p_{adj}=2.1×10^{-7}) and E2F4 (p_{adj}=5.5×10^{-5}) for upregulated DEGs and NFE2L2

for downregulated DEGs (p_{adj}=7.6×10^{-4}). *MYC* and *E2F4* were also themselves differentially expressed in

SSc compared to HCs in superficial cells (p_{adj}=7.8×10^{-5}, p_{adj}=9.8×10^{-4}, respectively). MYC was the most

enriched transcription factor in genes upregulated in GERD compared to HCs, but the enrichment was not

significant after adjusting for multiple testing (p_{adj}=0.11). No transcription factors were significantly

enriched in any pairwise comparison in the distal esophagus.

Fewer metallothioneins and metallothionein-expressing cells in superficial EECs in SSc

With SSc-specific dysregulation most prominent in the superficial cells of the proximal esophagus, we

performed sub-clustering of these cells to further examine corresponding expression patterns. We identified

five distinct clusters (**Figure 4A**) with unique expression marker patterns (**Figure 4B, Supplemental**

Figure 5A, Supplemental Table 13) and varying degrees of differentiation (**Figure 4C**). We then

performed label transfer onto the spatially mapped cells to confirm the physical distribution of these clusters

within the esophageal epithelium. Clusters 1 and 3 represented the apical, terminally differentiated

epithelial layers, as evidenced by their *FLG* expression[78-80] and spatial localization (**Figure 4D**), but cluster

3 had uniquely high expression of metallothioneins (**Figure 4B, Supplemental Figure 5A**). Cluster 2 was

distinguished by its relatively high *CTSV* expression, while clusters 4 and 5 were the least differentiated of

the superficial cells and were distinguished by their relative expression of *GJB6* and *FGFBP1*, respectively.

Cluster 3 was less abundant in SSc compared to HCs with $P<0.05$, while no other clusters demonstrated

significantly different abundances between SSc and HCs (**Figure 4E**). Metallothionein expression was also

significantly lower in SSc compared to HCs or GERD in each cluster, except for cluster 5 ($P<5\times10^{-14}$,

Figure 4, F-G). These observations were reproduced in the spatial imaging data, where cluster 3 was half

as abundant in SSc (14.5%) as in HCs (31.6%, **Figure 4D**) and metallothionein expression was likewise

significantly lower in SSc compared to HCs in clusters 1-4 ($P<1.5\times10^{-7}$, **Figure 4, H-I**). Moreover,

metallothionein expression was not significantly different between SSc and HCs in distal superficial cells

in the spatial imaging data (**Figure 4I**).

Regarding the expression of the significantly enriched transcription factors (IRF1, MYC, E2F4,

and NFE2L2; **Supplemental Table 12**) and their target genes, we observed several patterns (**Supplemental**

Figure 5, B-E). For *MYC*, *E2F4*, and *NFE2L2*, each gene's expression was highest on average in cluster 5,

the least differentiated superficial cluster (**Figure 4C**), and by condition was highest in SSc, followed by

GERD. Aggregate expression of target genes was positively correlated with transcription factor expression

for *MYC* (r=0.42) and *E2F4* (r=0.24) and negatively correlated for *IRF1* (r=-0.20) and *NFE2L2* (r=-0.18).

Correspondingly, cluster 5 featured the highest target gene expression for *MYC* and *E2F4* and lowest for

NFE2L2, and target gene expression differences relative to HCs were likewise correlated in SSc and GERD

but were more pronounced in SSc. Notably, several of the immune-related genes uniquely upregulated in

SSc (**Figure 3D; Supplemental Figure 4H**) displayed a similar expression pattern within superficial cells

as *MYC* and *E2F4*, with expression unique to cluster 5 (**Supplemental Figure 5F**, **Supplemental Table**

13). For *IRF1*, however, expression of the transcription factor and its target genes changes differed more in

GERD than in SSc relative to HCs.

***FLI1* not expressed in human EECs**

Deletion of the *Fli1* gene in epithelial cells in mice has been shown to recapitulate histological and

molecular features of esophageal involvement in SSc[25]. Therefore, we investigated the expression of *FLI1*

in our human esophageal samples. The expression of *FLI1* in human EECs was negligible and did not meet

the minimum expression thresholds for inclusion in our differential gene expression analysis. We did

observe low *FLI1* expression levels in endothelial cells (**Supplemental Figure 6A**), but the expression

differences between SSc, HCs, and GERD was not significant (**Supplemental Figure 6B**). There were

many FLI1 downstream targets among the proximal, superficial DEGs between SSc and HCs and seven

between SSc and GERD (*ARPC2*, *RAB24*, *MTPN*, *PPIF* upregulated; *CEBPZ*, *TRMT10C*, *TBP*

downregulated); however, the proportion of these genes among all DEGs was not different than what would

be expected by chance (P>0.05), and the average expression of FLI1 targets was higher in GERD and lower

in HCs compared to the expression in SSc (**Supplemental Figure 6C**).

Reduction of outer EECs and metallothionein expression correlates with loss of contractility in SSc

We next evaluated whether the cellular and molecular changes we observed between SSc, GERD, and HCs

were correlated with specific clinical measures of esophageal dysfunction (**Table 1**). To more efficiently

model the covariance structure among quantitative, functional esophageal measures in SSc (**Figure 5A**),

we performed PCA on a set of nine clinical metrics and tested for correlations with the first two PCs (**Figure 5B**). The first PC explained 45.5% of variance and was most correlated with FLIP intra-balloon pressure at 60ml (r=0.94), The second PC explained 22.6% of variance and was most correlated with HRM basal EGJ pressure (r=0.74).

We did not observe any significant associations between epithelial cell compartment proportions in SSc and esophageal motility phenotypes. It appeared that the low proportion of superficial cells in the esophageal epithelium was a universal feature in SSc, regardless of phenotype (**Supplemental Figure 7, A-B**). The proportion of superficial cells decreased with disease duration, but the trend was not statistically significant (P=0.1; **Supplemental Figure 7**C). We also did not observe any significant correlations between EEC compartment proportions and quantitative trait PCs (**Figure 5C**).

We then tested for correlations with gene expression in superficial EECs for genes that were significantly differentially expressed in SSc compared to HCs ($P_{adj}<0.05$) and nominally differentially expressed in SSc compared to GERD (P<0.05). There were 433 genes that met these criteria in the proximal esophagus and 99 in the distal esophagus. Although no associations with esophageal motility phenotypes were statistically significant after adjusting for multiple testing, the strongest phenotypic correlation was with *TRIM11* ($P_{FLIP}=0.01$, $P_{HRM}=0.007$, **Supplemental Figure 7D**), a gene recently found to attenuate Treg cell differentiation in CD4[+] T cells in mice[81]. No associations with the top two clinical PCs were significant after adjusting for multiple testing. We also assessed clinical PC correlations with aggregate metallothionein gene expression and transcription factor target expression for IRF1, MYC, E2F4, and NFE2L2. We observed one nominal association between the mean metallothionein module score and PC1 (P=0.02, **Figure 5D**). Notably, within superficial cells we also observed a strong correlation between the proportion of metallothionein-expressing cluster 3 cells and PC1 in the proximal (P=0.027) and distal esophagus ($P=9.7\times10^{-6}$; **Figure 5E**). This indicates that not only is this population of cells reduced in SSc, but its relative decrease is further correlated with more severe esophageal involvement (**Figure 5F**).

DISCUSSION

Esophageal dysfunction is extremely common in SSc and is significantly associated with increased mortality and lower quality of life[82,83]. The causal mechanisms by which SSc affects the esophagus, however, have not been conclusively determined. Here, we sought to clarify the role of epithelial cells in SSc esophageal dysfunction by using scRNA-seq to quantify cellular and transcriptional changes relative to HCs and individuals with GERD. While our findings suggest that epithelial changes in SSc result primarily from chronic acid exposure, they also highlight immunoregulatory pathways uniquely altered in SSc that may be linked to pathogenic aberrations.

The pathogenic role of epithelial cells in SSc has been an ongoing area of research[23]. When damaged, epithelial cells release signals that help induce fibroblast activation to promote wound healing[84]. In SSc, epidermal keratinocyte characteristics resemble a pro-fibrotic, activated state[85]. SSc epidermal cells were also found to stimulate fibroblasts in culture[86], and some signs related to epithelial-mesenchymal transition (EMT) have been observed in the SSc epidermis[87]. The FLI1 (friend leukemia integration 1) transcription factor, in particular, has received attention for its potential role in epithelial-cell-mediated SSc pathogenesis[23]. Lower FLI1 expression was observed in the epidermis of diffuse cutaneous SSc, and inactivation of FLI1 in human keratinocytes in vitro induced gene expression changes characteristic of SSc[25]. Furthermore, conditional deletion of *Fli1* in epithelial cells produced an SSc-like phenotype in mice[25]. Importantly, the epithelial-cell-specific *Fli1* knockout further recapitulated the esophageal involvement of SSc, with increased collagen deposition in the lamina propria combined with atrophy of the circular muscle layer, and the esophageal changes were not mediated by T-cell autoimmunity[25]. In contrast to these previous studies in mice and epidermal keratinocytes, we did not observe *FLI1* expression in EECs in any condition. *FLI1* was expressed at low levels in endothelial cells, but the expression differences between SSc, HCs, and GERD were not significant. We did observe significantly increased expression in SSc and GERD of the *PI3* gene, which encodes trappin-2/elafin, previously found to be induced by Fli1 silencing in human dermal microvascular endothelial cells[88]. However, this association is unlikely to be pathogenic, as the increase in gene expression was greater in GERD, and a growing body of evidence

indicates that trappin-2/elafin is expressed to promote tissue repair in response to gastrointestinal tissue

inflammation[89].

While there have been many studies of epithelial cells in skin in SSc, molecular study of the human

esophagus in SSc has heretofore been limited to one array-based gene expression study in bulk tissue

conducted by Taroni and colleagues[15], in which they identified distinct expression signatures among

variable genes between 15 individuals with SSc that were similar to those seen in skin[90]. These signatures

were independent of clinically defined SSc subsets[15], suggestive of inter-individual heterogeneity in SSc.

They also found that gene expression patterns between upper and lower esophageal biopsies within

individuals were nearly identical. They did not observe statistical associations between inflammatory gene

expression signatures and GERD, but the study was underpowered for such an analysis, and GERD was

defined based on histological evidence for basal cell hyperplasia and intraepithelial lymphocyte counts.

The gene expression differences we observed in SSc epithelial cells were highly correlated with

those seen in GERD, and nearly all differential gene expression was limited to the superficial layers of the

epithelium. These observations suggest that the primary driver of differential gene expression in EECs in

SSc is chronic acid exposure. The genes with the strongest mutual upregulation in SSc and GERD were

primarily related to keratinization/cornification, including small proline-rich proteins (SPRRs), serine

protease inhibitors (serpins), S100 proteins, late cornified envelope (LCE) genes, and keratins associated

with terminal epithelial differentiation, namely *KRTDAP* and *KRT*. *KRT1* helps maintain epithelial barrier

function in gastrointestinal epithelial cells, and its overexpression was shown to attenuate IL-1β-induced

epithelial permeability[91]. The mutual upregulation of these genes in the outer layers of the epithelium

therefore likely represent a protective response to chronic acid exposure.

While the overall gene expression differences were highly correlated between SSc and GERD,

there were sets of genes disproportionately upregulated in SSc that hint at disease-related immune response

aberrations, including genes that have previously been implicated in SSc pathogenesis. For example,

PTGES, which encodes prostaglandin E synthase, was previously found to be significantly upregulated in

SSc fibroblasts[92] and inflammatory non-classical monocytes[93], and Ptges-null mice were resistant to

bleomycin-induced fibrosis[92]. CD44 and CD74 form the receptor complex for the macrophage migration

inhibitory factor (MIF), an inflammatory cytokine that promotes fibroblast migration and has been

implicated in SSc pathogenesis[94]. LTB4R (Leukotriene B4 Receptor, or BLT1) has been found to activate

AKT/mTOR signaling and knockdown of *LTB4R* attenuated fibrosis in bleomycin-induced SSc in murine

models[95]. Serum HBEGF (heparin-binding epidermal growth factor) levels and fibroblast *HBEGF*

expression were both significantly elevated in SSc[96]. Copy number variation of *APOBEC3A* was

significantly associated with SSc in a Han Chinese population[97]. Finally, the SSc-specific upregulation of

genes involved in antigen processing and presentation (*HLA-B*, *CD74*, *TAP1*, *PSMB8*, *PSMB9*) are

suggestive of increased human leukocyte antigen (HLA) class I activity in superficial EECs in SSc. Notably,

TAP1, *PSMB8*, and *PSMB9* are located immediately adjacent to one another in the class II region of the

HLA locus, which is the genomic region with the strongest genetic associations with SSc[98], and SSc-

associated HLA-B alleles have also been identified[99,100].

The most striking set of genes that were uniquely downregulated in SSc were metallothioneins.

The expression of detected metallothioneins (*MT1A*, *MT1E*, *MT1F*, *MT1G*, *MT1H*, *MT1M*, *MT1X*, *MT2A*)

was strongly reduced in the superficial compartment of EECs in the proximal esophagus in SSc compared

to HCs. We further observed a nominal association between relative metallothionein expression in the

proximal esophagus and the first PC of esophageal dysmotility among SSc patients, with lower expression

of metallothioneins correlated with greater EGJ distensibility and weaker contractility. The proportion of

the primary metallothionein-expressing cluster within superficial EECs was likewise significantly

associated with clinical PC1. The metallothioneins are a family of well-conserved, metal-binding proteins

that regulate zinc and copper homeostasis, prevent heavy metal poisoning, and combat oxidative

stress[101,102]. Their study in a wide array of physiological conditions and immune-mediated diseases has

revealed the proteins play central roles in innate and adaptive immunity, including autoimmunity, but their

immunoregulatory behavior is highly complex and context-specific[101,102]. Given their import in immune

regulation, their associations with SSc and esophageal motility reported in this study, and the connection

between SSc and heavy metal exposure[103], the metallothioneins are compelling candidates that warrant

further study in SSc.

Interestingly, there was greater relative gene dysregulation in the proximal esophagus compared to

the distal esophagus in SSc, but the opposite was true for GERD. This discrepancy suggests that esophageal

dysmotility in SSc leads to greater acid exposure in the proximal esophagus, since refluxate typically affects

the distal esophagus significantly more than the proximal esophagus[104] and abnormal peristalsis prolongs

acid clearance[105]. This finding coincides with a bulk RNA-seq study of esophageal mucosa of achalasia

patients[106], which likewise identified more differential expression in the proximal esophagus than in the

distal esophagus, including significant enrichment of matrisome-associated genes and lower expression of

genes associated with reactive oxygen species metabolism[106]. Due to differences in innervation depth[107],

the epithelium of the proximal esophagus has more nociceptive sensitivity than the distal esophagus, which

likely contributes to the association between gastrointestinal symptoms and lower health-related quality of

life in SSc[108]. Proximal acid exposure increases the risk of aspiration[109] and is significantly more prevalent

in SSc patients with idiopathic lung fibrosis[110].

Targets for several transcription factors, including IRF1, MYC, E2F4, and NFE2L2 (or NRF2),

were significantly enriched among DEGs in superficial EECs from the proximal esophagus. IRF1 is

involved in innate immune responses, but while IRF1 targets were enriched in DEGs between SSc and

GERD, the enrichment appeared to be driven by upregulation in GERD. IRF1 targets were not enriched in

DEGs between SSc and HCs, nor was *IRF1* significantly differentially expressed in SSc. MYC, E2F4, and

NFE2L2 all participate in different stages of the cell cycle[111-113], and expression of each was highest in

either the proliferating basal or suprabasal compartments, but these proteins may also play a role in terminal

differentiation of EECs, particularly under conditions of stress. In the least differentiated superficial cluster

(cluster 5), where the expression differences relative to HCs for each of these transcription factors and their

targets was most pronounced, the expression level changes in GERD were correlated with those observed

in SSc. Furthermore, Myc ablation in Krt14-expressing tissues in mice led to abnormal terminal

differentiation of epithelial cells[114], and studies of the esophageal epithelium in Nrf2-knockout mice

indicate that Nrf2 regulates cornification of keratinized epithelial cells under oxidative stress[115,116].

Moreover, *C10orf99*—one of the genes uniquely upregulated in SSc with superficial expression mirroring

MYC, *E2F4*, and *NFE2L2*—was found to increase expression of proinflammatory markers and attenuate

late differentiation of keratinocytes under conditions of stress[117]. These findings therefore suggest that

within the SSc esophagus there is activation of pathways that regulate the late differentiation of EECs in

response to external stress, and these could contribute to the reduction of superficial EECs we observed in

SSc.

593   There are important limitations to consider when interpreting this study. First, this study only

focused on squamous epithelial cells. There may be relevant changes in other cell types within the

esophageal mucosa that correlate with SSc and dysmotility, but such analyses are ongoing and were outside

the scope of this investigation. Second, the relatively small patient sample size of this study combined with

the heterogeneity of SSc subtypes and dysmotility phenotypes limited our power to detect clinical

associations between cell type proportions or gene expression changes and specific clinical phenotypes.

Heterogeneous molecular profiles in SSc esophagus samples have been described previously[15], but we

grouped all SSc patients together in our analyses for comparisons against GERD and HCs. We applied

ordinal logistic regression on motility classifications and performed principal components analysis on

reflux- and motility-related quantitative traits to increase our power to detect clinical associations but were

nonetheless statistically limited by sample size. Third, our analysis of imaging data in the SSc esophageal

mucosa was limited. While the spatial molecular imaging confirmed our cell annotations and reproduced

our findings within the superficial compartment, CosMx's cell segmentation algorithm could not aptly

capture the flattened, densely packed outer cell layers of the epithelium, resulting in a relatively sparse

representation of superficial EECs. Furthermore, the spatial analysis was limited to 8 samples from 4

individuals. Therefore, we cannot make more robust conclusions on the morphological states that

accompany the transcriptional and cellular proportion changes that we observed. Future studies utilizing

larger, more homogeneous cohorts with complete imaging data may be able to detect more esophageal

epithelial changes associated with dysmotility in SSc.

In summary, esophageal complications are common in individuals with SSc and can greatly impact

quality of life and lifespan. In this study, we sought to deepen our understanding of the role of the epithelium

in SSc esophageal involvement. Through a thorough, single-cell-level transcriptomic investigation, we

identified the unique cellular and transcriptional differences present in the SSc esophageal epithelium.

There were significantly fewer terminally differentiated epithelial cells in the apical, superficial layers in

both the proximal and distal esophagus, but otherwise epithelial compartment proportions were similar to

healthy controls, including proliferating cell proportions. Significant differences in gene expression were

likewise almost exclusively found in the superficial compartment, and these changes were highly correlated

with those seen in individuals with GERD, indicating that the primary driver of differential gene expression

in the SSc esophageal epithelium is chronic acid exposure. Transcriptional differences were more

prominent in the proximal esophagus of SSc patients than in GERD patients, possibly due to greater

proximal exposure resulting from esophageal dysmotility. Genes that were most disproportionately

dysregulated in SSc compared to GERD belonged to immune-related pathways, including innate and

adaptive response, antigen presentation, and metal homeostasis, pointing to pathogenic immune

dysfunction. Future studies investigating these pathways in non-epithelial cell populations in more

homogeneous SSc cohorts may further resolve the pathogenesis of esophageal involvement in SSc. By

serving as an atlas for the human esophageal epithelium in SSc, this study can guide future efforts to address

remaining gaps in our understanding of the SSc esophagus, to ultimately uncover pathogenic mechanisms

and identify actionable targets.

REFERENCES

1. Bairkdar, M. *et al.* Incidence and prevalence of systemic sclerosis globally: a comprehensive systematic review and meta-analysis. *Rheumatology (Oxford)* **60**, 3121-3133 (2021).
2. Fan, Y., Bender, S., Shi, W. & Zoz, D. Incidence and prevalence of systemic sclerosis and systemic sclerosis with interstitial lung disease in the United States. *J Manag Care Spec Pharm* **26**, 1539-1547 (2020).
3. Tian, J. *et al.* Global, regional, and national incidence and prevalence of systemic sclerosis. *Clin Immunol* **248**, 109267 (2023).
4. Pope, J.E. *et al.* Systemic Sclerosis and Associated Interstitial Lung Disease in Ontario, Canada: An Examination of Prevalence and Survival Over 10 Years. *J Rheumatol* **48**, 1427-1434 (2021).
5. Li, J.X. Secular Trends in Systemic Sclerosis Mortality in the United States from 1981 to 2020. *Int J Environ Res Public Health* **19**(2022).
6. Rubio-Rivas, M., Royo, C., Simeon, C.P., Corbella, X. & Fonollosa, V. Mortality and survival in systemic sclerosis: systematic review and meta-analysis. *Semin Arthritis Rheum* **44**, 208-19 (2014).
7. Bairkdar, M. *et al.* Survival in Swedish patients with systemic sclerosis: a nationwide population-based matched cohort study. *Rheumatology (Oxford)* **62**, 1170-1178 (2023).
8. Li, B. *et al.* Esophageal Dysfunction in Systemic Sclerosis: An Update. *Rheumatol Ther* **8**, 1535-1549 (2021).
9. Emmanuel, A. Current management of the gastrointestinal complications of systemic sclerosis. *Nat Rev Gastroenterol Hepatol* **13**, 461-72 (2016).
10. Ahuja, N.K. & Clarke, J.O. Scleroderma and the Esophagus. *Gastroenterol Clin North Am* **50**, 905-918 (2021).
11. Denaxas, K., Ladas, S.D. & Karamanolis, G.P. Evaluation and management of esophageal manifestations in systemic sclerosis. *Ann Gastroenterol* **31**, 165-170 (2018).
12. Foocharoen, C. *et al.* Development and validation of machine learning for early mortality in systemic sclerosis. *Sci Rep* **12**, 17178 (2022).
13. Sjogren, R.W. Gastrointestinal motility disorders in scleroderma. *Arthritis Rheum* **37**, 1265-82 (1994).
14. Roberts, C.G., Hummers, L.K., Ravich, W.J., Wigley, F.M. & Hutchins, G.M. A case-control study of the pathology of oesophageal disease in systemic sclerosis (scleroderma). *Gut* **55**, 1697-703 (2006).
15. Taroni, J.N. *et al.* Molecular characterization of systemic sclerosis esophageal pathology identifies inflammatory and proliferative signatures. *Arthritis Res Ther* **17**, 194 (2015).
16. Roman, S. *et al.* Esophageal dysmotility associated with systemic sclerosis: a high-resolution manometry study. *Dis Esophagus* **24**, 299-304 (2011).
17. Noviani, M., Chellamuthu, V.R., Albani, S. & Low, A.H.L. Toward Molecular Stratification and Precision Medicine in Systemic Sclerosis. *Front Med (Lausanne)* **9**, 911977 (2022).
18. Carlson, D.A. *et al.* Loss of Peristaltic Reserve, Determined by Multiple Rapid Swallows, Is the Most Frequent Esophageal Motility Abnormality in Patients With Systemic Sclerosis. *Clin Gastroenterol Hepatol* **14**, 1502-6 (2016).
19. Kimmel, J.N. *et al.* The association between systemic sclerosis disease manifestations and esophageal high-resolution manometry parameters. *Neurogastroenterol Motil* **28**, 1157-65 (2016).
20. Carlson, D.A. *et al.* Heterogeneity of primary and secondary peristalsis in systemic sclerosis: A new model of "scleroderma esophagus". *Neurogastroenterol Motil* **34**, e14284 (2022).
21. Durcan, C. *et al.* Experimental investigations of the human oesophagus: anisotropic properties of the embalmed mucosa-submucosa layer under large deformation. *Biomech Model Mechanobiol* **21**, 1685-1702 (2022).
22. Kou, W., Pandolfino, J.E., Kahrilas, P.J. & Patankar, N.A. Simulation studies of the role of esophageal mucosa in bolus transport. *Biomech Model Mechanobiol* **16**, 1001-1009 (2017).

23.   Asano, Y., Takahashi, T. & Saigusa, R. Systemic sclerosis: Is the epithelium a missing piece of the
pathogenic puzzle? *J Dermatol Sci* **94**, 259-265 (2019).
24.   Asano, Y., Bujor, A.M. & Trojanowska, M. The impact of Fli1 deficiency on the pathogenesis of
systemic sclerosis. *J Dermatol Sci* **59**, 153-62 (2010).
25.   Takahashi, T. *et al.* Epithelial Fli1 deficiency drives systemic autoimmunity and fibrosis: Possible
roles in scleroderma. *J Exp Med* **214**, 1129-1151 (2017).
26.   Dinh, H.Q. *et al.* Integrated single-cell transcriptome analysis reveals heterogeneity of esophageal
squamous cell carcinoma microenvironment. *Nat Commun* **12**, 7335 (2021).
27.   Zhang, X. *et al.* Dissecting esophageal squamous-cell carcinoma ecosystem by single-cell
transcriptomic analysis. *Nat Commun* **12**, 5291 (2021).
28.   Rochman, M. *et al.* Single-cell RNA-Seq of human esophageal epithelium in homeostasis and
allergic inflammation. *JCI Insight* **7**(2022).
29.   Clevenger, M.H. *et al.* Suprabasal cells retain progenitor cell identity programs in eosinophilic
esophagitis-driven basal cell hyperplasia. *JCI Insight* **8**(2023).
30.   Carlson, D.A. *et al.* Classifying Esophageal Motility by FLIP Panometry: A Study of 722 Subjects
With Manometry. *Am J Gastroenterol* **116**, 2357-2366 (2021).
31.   Koop, A.H., Kahrilas, P.J., Schauer, J., Pandolfino, J.E. & Carlson, D.A. The impact of primary
peristalsis, contractile reserve, and secondary peristalsis on esophageal clearance measured by
timed barium esophagogram. *Neurogastroenterol Motil*, e14638 (2023).
32.   Stern, E.K. *et al.* Abnormal esophageal acid exposure on high-dose proton pump inhibitor therapy
is common in systemic sclerosis patients. *Neurogastroenterol Motil* **30**(2018).
33.   Yadlapati, R. *et al.* Esophageal motility disorders on high-resolution manometry: Chicago
classification version 4.0((c)). *Neurogastroenterol Motil* **33**, e14058 (2021).
34.   Rooney, K.P. *et al.* Esophagogastric Junction Opening Parameters Are Consistently Abnormal in
Untreated Achalasia. *Clin Gastroenterol Hepatol* **19**, 1058-1060.e1 (2021).
35.   Carlson, D.A. *et al.* Evaluating esophageal motility beyond primary peristalsis: Assessing
esophagogastric junction opening mechanics and secondary peristalsis in patients with normal
manometry. *Neurogastroenterol Motil* **33**, e14116 (2021).
36.   Carlson, D.A. *et al.* Normal Values of Esophageal Distensibility and Distension-Induced
Contractility Measured by Functional Luminal Imaging Probe Panometry. *Clin Gastroenterol
Hepatol* **17**, 674-681 e1 (2019).
37.   Jonasson, C., Wernersson, B., Hoff, D.A. & Hatlebakk, J.G. Validation of the GerdQ questionnaire
for the diagnosis of gastro-oesophageal reflux disease. *Aliment Pharmacol Ther* **37**, 564-72 (2013).
38.   Taft, T.H. *et al.* Development and validation of the brief esophageal dysphagia questionnaire.
Neurogastroenterol Motil **28**, 1854-1860 (2016).
39.   Bedell, A., Taft, T.H., Keefer, L. & Pandolfino, J. Development of the Northwestern Esophageal
Quality of Life Scale: A Hybrid Measure for Use Across Esophageal Conditions. *Am J
Gastroenterol* **111**, 493-9 (2016).
40.   Hao, Y. *et al.* Integrated analysis of multimodal single-cell data. *Cell* **184**, 3573-3587 e29 (2021).
41.   Hippen, A.A. *et al.* miQC: An adaptive probabilistic framework for quality control of single-cell
RNA-sequencing data. *PLoS Comput Biol* **17**, e1009290 (2021).
42.   Germain, P.L., Lun, A., Garcia Meixide, C., Macnair, W. & Robinson, M.D. Doublet identification
in single-cell sequencing data using scDblFinder. *F1000Res* **10**, 979 (2021).
43.   Hafemeister, C. & Satija, R. Normalization and variance stabilization of single-cell RNA-seq data
using regularized negative binomial regression. *Genome Biol* **20**, 296 (2019).
44.   Lause, J., Berens, P. & Kobak, D. Analytic Pearson residuals for normalization of single-cell RNA-
seq UMI data. *Genome Biol* **22**, 258 (2021).
45.   McInnes, L., Healy, J. & Melville, J. UMAP: Uniform Manifold Approximation and Projection for
Dimension Reduction. arXiv:1802.03426 (2018).
46.   Busslinger, G.A. *et al.* Human gastrointestinal epithelia of the esophagus, stomach, and duodenum
resolved at single-cell resolution. *Cell Rep* **34**, 108819 (2021).

47.   Kabir, M.F. *et al.* Single cell transcriptomic analysis reveals cellular diversity of murine esophageal
epithelium. *Nat Commun* **13**, 2167 (2022).

48.   Okumura, T., Shimada, Y., Imamura, M. & Yasumoto, S. Neurotrophin receptor p75(NTR)
characterizes human esophageal keratinocyte stem cells in vitro. *Oncogene* **22**, 4017-26 (2003).

49.   Tirosh, I. *et al.* Dissecting the multicellular ecosystem of metastatic melanoma by single-cell RNA-
seq. *Science* **352**, 189-96 (2016).

50.   Fonseka, C.Y. *et al.* Mixed-effects association of single cells identifies an expanded effector
CD4(+) T cell subset in rheumatoid arthritis. *Sci Transl Med* **10**(2018).

51.   Mootha, V.K. *et al.* PGC-1alpha-responsive genes involved in oxidative phosphorylation are
coordinately downregulated in human diabetes. *Nat Genet* **34**, 267-73 (2003).

52.   Subramanian, A. *et al.* Gene set enrichment analysis: a knowledge-based approach for interpreting
genome-wide expression profiles. *Proc Natl Acad Sci U S A* **102**, 15545-50 (2005).

53.   Liberzon, A. *et al.* The Molecular Signatures Database (MSigDB) hallmark gene set collection. *Cell*
Syst **1**, 417-425 (2015).

54.   Chen, Y., Lun, A.T. & Smyth, G.K. From reads to genes to pathways: differential expression
analysis of RNA-Seq experiments using Rsubread and the edgeR quasi-likelihood pipeline.
F1000Res **5**, 1438 (2016).

55.   McCarthy, D.J., Chen, Y. & Smyth, G.K. Differential expression analysis of multifactor RNA-Seq
experiments with respect to biological variation. *Nucleic Acids Res* **40**, 4288-97 (2012).

56.   Robinson, M.D., McCarthy, D.J. & Smyth, G.K. edgeR: a Bioconductor package for differential
expression analysis of digital gene expression data. *Bioinformatics* **26**, 139-40 (2010).

57.   Wu, T. *et al.* clusterProfiler 4.0: A universal enrichment tool for interpreting omics data. *Innovation*
(Camb) **2**, 100141 (2021).

58.   Consortium, E.P. An integrated encyclopedia of DNA elements in the human genome. *Nature* **489**,
57-74 (2012).

59.   Lachmann, A. *et al.* ChEA: transcription factor regulation inferred from integrating genome-wide
ChIP-X experiments. *Bioinformatics* **26**, 2438-44 (2010).

60.   Kou, Y. *et al.* ChEA2: Gene-Set Libraries from ChIP-X Experiments to Decode the Transcription
Regulome. 416-430 (Springer Berlin Heidelberg, Berlin, Heidelberg, 2013).

61.   Chen, E.Y. *et al.* Enrichr: interactive and collaborative HTML5 gene list enrichment analysis tool.
BMC Bioinformatics **14**, 128 (2013).

62.   Aran, D. *et al.* Reference-based analysis of lung single-cell sequencing reveals a transitional
profibrotic macrophage. *Nat Immunol* **20**, 163-172 (2019).

63.   Koop, A.H., Kahrilas, P.J., Schauer, J., Pandolfino, J.E. & Carlson, D.A. The impact of primary
peristalsis, contractile reserve, and secondary peristalsis on esophageal clearance measured by
timed barium esophagogram. *Neurogastroenterol Motil* **35**, e14638 (2023).

64.   Squair, J.W. *et al.* Confronting false discoveries in single-cell differential expression. *Nat Commun*
12, 5692 (2021).

65.   Wang, Q. *et al.* Targeting microsomal prostaglandin E synthase 1 to develop drugs treating the
inflammatory diseases. *Am J Transl Res* **13**, 391-419 (2021).

66.   Yi, Y.S. Functional Role of Milk Fat Globule-Epidermal Growth Factor VIII in Macrophage-
Mediated Inflammatory Responses and Inflammatory/Autoimmune Diseases. *Mediators Inflamm*
2016, 5628486 (2016).

67.   Baaten, B.J., Li, C.R. & Bradley, L.M. Multifaceted regulation of T cells by CD44. *Commun Integr*
Biol **3**, 508-12 (2010).

68.   Liu, Q. *et al.* Role of the mucin-like glycoprotein FCGBP in mucosal immunity and cancer. *Front*
Immunol **13**, 863317 (2022).

69.   Oh, S. *et al.* Genotoxic stress and viral infection induce transient expression of APOBEC3A and
pro-inflammatory genes through two distinct pathways. *Nat Commun* **12**, 4917 (2021).

70.   Tiwari, R., de la Torre, J.C., McGavern, D.B. & Nayak, D. Beyond Tethering the Viral Particles:
Immunomodulatory Functions of Tetherin (BST-2). *DNA Cell Biol* **38**, 1170-1177 (2019).

71.   Nguyen, H.T. *et al.* CXCR7: a beta-arrestin-biased receptor that potentiates cell migration and
recruits beta-arrestin2 exclusively through Gbetagamma subunits and GRK2. *Cell Biosci* **10**, 134
(2020).
72.   Okamoto, Y. & Shikano, S. Emerging roles of a chemoattractant receptor GPR15 and ligands in
pathophysiology. *Front Immunol* **14**, 1179456 (2023).
73.   Subramanian, B.C., Moissoglu, K. & Parent, C.A. The LTB(4)-BLT1 axis regulates the polarized
trafficking of chemoattractant GPCRs during neutrophil chemotaxis. *J Cell Sci* **131**(2018).
74.   Kelly, A. & Trowsdale, J. Genetics of antigen processing and presentation. *Immunogenetics* **71**,
161-170 (2019).
75.   Bartel, Y., Bauer, B. & Steinle, A. Modulation of NK cell function by genetically coupled C-type
lectin-like receptor/ligand pairs encoded in the human natural killer gene complex. *Front Immunol*
4, 362 (2013).
76.   Li, Y. *et al.* HB-EGF-induced IL-8 secretion from airway epithelium leads to lung fibroblast
proliferation and migration. *BMC Pulm Med* **21**, 347 (2021).
77.   Lu, R.Q. *et al.* SGK1, a Critical Regulator of Immune Modulation and Fibrosis and a Potential
Therapeutic Target in Chronic Graft-Versus-Host Disease. *Front Immunol* **13**, 822303 (2022).
78.   Uhlen, M. *et al.* Proteomics. Tissue-based map of the human proteome. *Science* **347**, 1260419
(2015).
79.   Politi, E. *et al.* Filaggrin and Periostin Expression Is Altered in Eosinophilic Esophagitis and
Normalized With Treatment. *J Pediatr Gastroenterol Nutr* **65**, 47-52 (2017).
80.   Oshima, N. *et al.* Epidermal differentiation complex protein involucrin is down-regulated in
eosinophilic esophagitis. *Esophagus* **14**, 171-177 (2017).
81.   Yu, T. *et al.* TRIM11 attenuates Treg cell differentiation by p62-selective autophagic degradation
of AIM2. *Cell Rep* **42**, 113231 (2023).
82.   Crowell, M.D. *et al.* Esophageal Motor Abnormalities in Patients With Scleroderma:
Heterogeneity, Risk Factors, and Effects on Quality of Life. *Clin Gastroenterol Hepatol* **15**, 207-
213 e1 (2017).
83.   Forbes, A. & Marie, I. Gastrointestinal complications: the most frequent internal complications of
systemic sclerosis. *Rheumatology (Oxford)* **48 Suppl 3**, iii36-9 (2009).
84.   Krieg, T., Abraham, D. & Lafyatis, R. Fibrosis in connective tissue disease: the role of the
myofibroblast and fibroblast-epithelial cell interactions. *Arthritis Res Ther* **9 Suppl 2**, S4 (2007).
85.   Aden, N. *et al.* Proteomic analysis of scleroderma lesional skin reveals activated wound healing
phenotype of epidermal cell layer. *Rheumatology (Oxford)* **47**, 1754-60 (2008).
86.   Aden, N. *et al.* Epithelial cells promote fibroblast activation via IL-1alpha in systemic sclerosis. *J*
Invest Dermatol **130**, 2191-200 (2010).
87.   Nikitorowicz-Buniak, J., Denton, C.P., Abraham, D. & Stratton, R. Partially Evoked Epithelial-
Mesenchymal Transition (EMT) Is Associated with Increased TGFbeta Signaling within Lesional
Scleroderma Skin. *PLoS One* **10**, e0134092 (2015).
88.   Miyagawa, T. *et al.* A potential contribution of trappin-2 to the development of vasculopathy in
systemic sclerosis. *J Eur Acad Dermatol Venereol* **33**, 753-760 (2019).
89.   Deraison, C., Bonnart, C., Langella, P., Roget, K. & Vergnolle, N. Elafin and its precursor trappin-
2: What is their therapeutic potential for intestinal diseases? *Br J Pharmacol* **180**, 144-160 (2023).
90.   Hinchcliff, M. *et al.* Molecular signatures in skin associated with clinical improvement during
mycophenolate treatment in systemic sclerosis. *J Invest Dermatol* **133**, 1979-89 (2013).
91.   Dong, X. *et al.* Critical role of Keratin 1 in maintaining epithelial barrier and correlation of its
down-regulation with the progression of inflammatory bowel disease. *Gene* **608**, 13-19 (2017).
92.   McCann, M.R. *et al.* mPGES-1 null mice are resistant to bleomycin-induced skin fibrosis. *Arthritis*
Res Ther **13**, R6 (2011).
93.   Villanueva-Martin, G. *et al.* Non-classical circulating monocytes expressing high levels of
microsomal prostaglandin E2 synthase-1 tag an aberrant IFN-response in systemic sclerosis. *J*
Autoimmun **140**, 103097 (2023).

94. Unlu, B., Tursen, U., Rajabi, Z., Jabalameli, N. & Rajabi, F. The Immunogenetics of Systemic
Sclerosis. *Adv Exp Med Biol* **1367**, 259-298 (2022).
95. Liang, M. *et al.* Promotion of Myofibroblast Differentiation and Tissue Fibrosis by the Leukotriene
B(4) -Leukotriene B(4) Receptor Axis in Systemic Sclerosis. *Arthritis Rheumatol* **72**, 1013-1025
(2020).
96. Hirabayashi, M. *et al.* Possible pro-inflammatory role of heparin-binding epidermal growth factor-
like growth factor in the active phase of systemic sclerosis. *J Dermatol* **45**, 182-188 (2018).
97. Guo, S. *et al.* Copy Number Variation of HLA-DQA1 and APOBEC3A/3B Contribute to the
Susceptibility of Systemic Sclerosis in the Chinese Han Population. *J Rheumatol* **43**, 880-6 (2016).
98. Lopez-Isac, E. *et al.* GWAS for systemic sclerosis identifies multiple risk loci and highlights
fibrotic and vasculopathy pathways. *Nat Commun* **10**, 4955 (2019).
99. Acosta-Herrera, M. *et al.* Comprehensive analysis of the major histocompatibility complex in
systemic sclerosis identifies differential HLA associations by clinical and serological subtypes. *Ann
Rheum Dis* **80**, 1040-1047 (2021).
100. Hanson, A.L. *et al.* Contribution of HLA and KIR Alleles to Systemic Sclerosis Susceptibility and
Immunological and Clinical Disease Subtypes. *Front Genet* **13**, 913196 (2022).
101. Dai, H., Wang, L., Li, L., Huang, Z. & Ye, L. Metallothionein 1: A New Spotlight on Inflammatory
Diseases. *Front Immunol* **12**, 739918 (2021).
102. Subramanian Vignesh, K. & Deepe, G.S., Jr. Metallothioneins: Emerging Modulators in Immunity
and Infection. *Int J Mol Sci* **18**(2017).
103. Marie, I. Systemic sclerosis and exposure to heavy metals. *Autoimmun Rev* **18**, 62-72 (2019).
104. Shaker, R., Dodds, W.J., Helm, J.F., Kern, M.K. & Hogan, W.J. Regional esophageal distribution
and clearance of refluxed gastric acid. *Gastroenterology* **101**, 355-9 (1991).
105. Diener, U., Patti, M.G., Molena, D., Fisichella, P.M. & Way, L.W. Esophageal dysmotility and
gastroesophageal reflux disease. *J Gastrointest Surg* **5**, 260-5 (2001).
106. Patel, C.K. *et al.* RNA-sequencing reveals molecular and regional differences in the esophageal
mucosa of achalasia patients. *Sci Rep* **12**, 20616 (2022).
107. Woodland, P. *et al.* Distinct afferent innervation patterns within the human proximal and distal
esophageal mucosa. *Am J Physiol Gastrointest Liver Physiol* **308**, G525-31 (2015).
108. Sandqvist, G. & Hesselstrand, R. Validity of the Swedish version of the systemic sclerosis quality
of life questionnaire (SSCQoL): A novel measure of quality of life for patients with systemic
sclerosis. *Ann Rheum Dis* **78**, 855-857 (2019).
109. Lee, A.S., Lee, J.S., He, Z. & Ryu, J.H. Reflux-Aspiration in Chronic Lung Disease. *Ann Am
Thorac Soc* **17**, 155-164 (2020).
110. Savarino, E. *et al.* Gastroesophageal reflux and pulmonary fibrosis in scleroderma: a study using
pH-impedance monitoring. *Am J Respir Crit Care Med* **179**, 408-13 (2009).
111. Conboy, C.M. *et al.* Cell cycle genes are the evolutionarily conserved targets of the E2F4
transcription factor. *PLoS One* **2**, e1061 (2007).
112. Garcia-Gutierrez, L., Delgado, M.D. & Leon, J. MYC Oncogene Contributions to Release of Cell
Cycle Brakes. *Genes (Basel)* **10**(2019).
113. Lastra, D., Escoll, M. & Cuadrado, A. Transcription Factor NRF2 Participates in Cell Cycle
Progression at the Level of G1/S and Mitotic Checkpoints. *Antioxidants (Basel)* **11**(2022).
114. Portal, C., Wang, Z., Scott, D.K., Wolosin, J.M. & Iomini, C. The c-Myc Oncogene Maintains
Corneal Epithelial Architecture at Homeostasis, Modulates p63 Expression, and Enhances
Proliferation During Tissue Repair. *Invest Ophthalmol Vis Sci* **63**, 3 (2022).
115. Wruck, C.J. *et al.* Impact of Nrf2 on esophagus epithelium cornification. *Int J Dermatol* **50**, 1362-
1365 (2011).
116. Chen, H. *et al.* Nrf2 deficiency impairs the barrier function of mouse oesophageal epithelium. *Gut*
63, 711-9 (2014).
117. Dainichi, T. *et al.* C10orf99/GPR15L Regulates Proinflammatory Response of Keratinocytes and
Barrier Formation of the Skin. *Front Immunol* **13**, 825032 (2022).

118.   Jones, R. *et al.* Development of the GerdQ, a tool for the diagnosis and management of gastro-
885   oesophageal reflux disease in primary care. *Aliment Pharmacol Ther* **30**, 1030-8 (2009).
886

FIGURES

Figure 1. ScRNA-seq sample composition by cell type. A) Integrated UMAP embedding of all cells

(n=306,372) labeled by cell type. **B)** Proportion of cells by cell type. **C)** Expression by cell type of canonical

markers. **D)** Sample-wise (n=39) distribution of major cell types. **E)** Proportion of major non-epithelial cell

types by condition and biopsy location. Box whiskers extend to range of values.

Figure 2. Landscape of esophageal epithelial cells. A) Histological summary of the human esophageal

epithelium, adopted from Clevenger et al.[29] Alternatively shaded cells within the same layer represent

proliferating cells. NOTE: The layers of replicating cells not attached to the basement membrane, labeled

here as proliferating suprabasal cells, are sometimes referred to as epibasal cells[29]. **B)** Integrated UMAP

embedding of all esophageal epithelial cells (EECs, n=230,720) labeled by epithelial compartment. **C)**

Expression of EEC compartment and cell cycle markers by condition. **D)** CosMx spatial molecular imaging

of proximal and distal esophageal mucosal tissue in scleroderma with absent contractility, annotated using

label transfer from the scRNA-seq data. **E)** Proportions of cells by condition, EEC compartment, and biopsy

location. The bars denote the mean values, the vertical lines the standard deviations, and the points the

individual sample proportions. Pairwise differences across conditions were evaluated statistically using

MASC[50]. *$p<0.05$.

Figure 3. Differential gene expression between conditions in esophageal epithelial cells. A) The

number of significantly differentially expressed genes at the single-cell level with $|\log_2 FC| >0.1$ are shown

for SSC vs. HCs (purple) and GERD vs. HCs (orange), by epithelial compartment and biopsy location. Blue

bars account for genes that were differentially expressed in both SSc and GERD compared to HCs. **B)**

Gene set enrichment analysis results, showing all pathways enriched with $P<0.001$ (unadjusted) for SSc

vs. HCs (purple) and GERD vs. HCs (orange), split by non-proliferating epithelial compartment and biopsy

location. Points circled in red indicate statistical significance after adjusting for the number of tested

pathways ($P_{FDR}<0.05$). Pathways in bold denote pathways with significant enrichment in SSc. **C)** The

distribution of intra-sample EEC gene expression correlations for the 2,000 most variable genes between

proximal and distal biopsies are shown by epithelial compartment and condition. Box whiskers extend to

range of values. **D)** Pseudobulk gene expression differences in $\log_2$FC are shown for SSc vs. HCs (Y axis)

against GERD vs. HCs (X axis) within the superficial compartment in the proximal and distal esophagus

regions. Significant DEGs in both conditions are highlighted in blue, significant DEGs in SSC only are

highlighted in purple, and significant DEGs in GERD only are highlighted in orange. The correlation between

comparisons is shown in the upper left, and the slope and coefficient of determination for the modeled linear

regression with intercept=0 is displayed in the lower right. Trendlines with 95% confidence intervals are

plotted in pink, and the dashed grey lines denote where y=x. Encircled points highlight disease-specific

DEGs that are referenced in the main text and plotted in **Supplemental Figure 4H**, which shows the

distribution of expression aggregated by sample in the superficial compartment across conditions and

biopsy locations.

Figure 4. Landscape of superficial esophageal epithelial cells. A) Integrated UMAP embedding of all

superficial EECs (n=30,866) clustered by unique transcriptional signatures. **B)** Relative expression of

cluster-specific gene signatures. **C)** Superficial module score by superficial cell cluster. **D)** CosMx spatial

molecular imaging of proximal esophageal mucosal tissue from a healthy control donor and in scleroderma

with absent contractility, annotated using label transfer from the scRNA-seq data. Superficial cluster

proportions were derived from all imaged proximal tissue (n=2 SSc, 2 HCs). **E)** Proportion of superficial

cells by condition and cluster from the proximal esophagus. The bars denote the mean values, the vertical

lines the standard deviations, and the points the individual sample proportions. Pairwise differences across

conditions were evaluated statistically using MASC[50]. *p<0.05; **p<0.005. **F)** Distribution of metallothionein

module score in proximal, superficial cells by condition. The metallothionein module score included *MT1A*,

MT1E, *MT1F*, *MT1G*, *MT1H*, *MT1M*, *MT1X*, and *MT2A*. **G)** Distribution of relative metallothionein

expression by cluster and condition in superficial cells from proximal esophagus. All pairwise comparisons

between SSc and HCs were statistically significant, except for cluster 5. **H)** CosMx spatial molecular

imaging of proximal esophageal mucosal tissue from a healthy control donor and in scleroderma with

absent contractility. Metallothionein module scores are plotted within the superficial EECs. **I)** Distributions

of metallothionein module scores by cell cluster and condition from the CosMx spatial molecular imaging

data. Clusters withs significant pairwise differences (Wilcoxon) in module score levels (P_{FDR}<0.05) are

denoted with an asterisk.

Figure 5. Correlations with clinical phenotypes. A) Heatmap of quantitative clinical traits organized using

agglomerative, complete hierarchical clustering on Euclidean distances, with pairwise Spearman

correlations shown in each cell. **B)** SSc cases are plotted on the first two PCs of the quantitative clinical

traits, colored by esophageal motility phenotype. The relative magnitude and direction of trait correlations

with the PCs are shown with black arrows. **C)** Correlations between EEC compartments and clinical trait

PCs in SSc cases. Linear regression trendlines with 95% confidence intervals are shown for each

compartment against PC1 and PC2. **D)** Correlations between aggregate, relative metallothionein

expression and clinical trait PCs in superficial cells in the proximal esophagus. Trendlines with 95%

confidence intervals are shown with the unadjusted correlation P-value. The metallothionein module score

included *MT1A*, *MT1E*, *MT1F*, *MT1G*, *MT1H*, *MT1M*, *MT1X*, and *MT2A*. **E)** Correlations between superficial

clusters (SCs) and clinical trait PC1 in SSc cases. Linear regression trendlines with 95% confidence

intervals are shown for each SC. The displayed P-values correspond to the highlighted correlations

between SC3 and PC1. **F)** Boxplots showing the proportion of SC3 in superficial cells by esophageal motility

phenotype in the proximal and distal esophagus, colored by disease state (HCs, grey; GERD, orange; SSc,

purple). AET, acid exposure time; BEDQ, brief esophageal dysphagia questionnaire; BMI, body mass index;

DCI, distal contractile integral; DI, distensibility index; EGJ, esophagogastric junction; EGJOO,

esophagogastric junction outflow obstruction; FLIP, functional luminal imaging probe panometry; HCs,

healthy controls; HRM, high-resolution manometry; IEM, ineffective esophageal motility; IQR, inter-quartile

range; IRP, integrated relaxation pressure; NEQOL, Northwestern esophageal quality of life; NM,

neuromyogenic model. NR, not reported.

SUPPLEMENTAL FIGURES

Supplemental Figure 1. Cell clustering and cell type annotation. A) Cell type module scores for 10

detected cell types, colored by relative gene expression of the listed genes. **B)** Projected UMAP

embeddings calculated on the top 40 PCs with n=200 neighbors. Cells are colored by cluster, which are

numbered in descending order by total cell count. Clusters were determined using Seurat's modularity-

based clustering on a shared nearest neighbor (SNN) graph with k=25 and resolution=0.25 on the top 40

PCs. **C)** Isolation of cluster 13 for annotation of cell types with smaller proportions of cells and projected

UMAP embeddings for cluster 13, colored by subcluster. **D)** Cell type module scores for 7 detected cell

types in subcluster 13, colored by relative gene expression of the listed genes.

Supplemental Figure 2. Epithelial cell quality control and annotation. A) EEC UMAP projection,

colored by the number of unique molecular identifiers (UMIs) per cell. **B)** EEC UMAP projection, colored by

the number of detected genes per cell. **C)** EEC UMAP projection, colored by the number of proportion of

UMIs mapping to mitochondrial DNA. **D)** EEC UMAP projection, colored by the proportion of UMIs mapping

to ribosomal DNA. **E)** Distribution of number of UMIs detected per cell. EECs with <3500 UMIs/cell were

removed from further analysis. **F)** EEC UMAPs colored by gene expression (log(counts+1))) for genes

included in compartment-specific expression scores. **G)** EEC UMAPs colored by compartment expression

scores. **H)** Projected UMAP embeddings for post-quality-control EECs calculated on the top 35 PCs with

n=100 neighbors. Cells are colored by cluster, which are numbered in descending order by total cell count.

Clusters were determined using Seurat's modularity-based clustering on a SNN graph with k=50 and

resolution=0.25 on the top 35 PCs. **I)** Result of K-means clustering to distinguish suprabasal from basal

cells, based on expression of corresponding cluster markers (**F**) in clusters 3, 4, and 5, with K=2. **J)** Result

of K-means clustering to distinguish superficial from suprabasal cells, based on expression of

corresponding cluster markers (**F**) in clusters 6, 7, and 8, with K=2. **K)** Predicted classification of cell cycle

state in EECs determined using Seurat's CellCycleScoring() function.

Supplemental Figure 3. Spatial molecular imaging of esophageal mucosa. A) Esophageal mucosa tissue slides analyzed by CosMx spatial molecular imaging are shown with annotations conferred from scRNA-seq label transfer for two healthy controls (HCs) and two SSc patients with absent contractility **B)** Spatial molecular imaging cell type counts are shown by individual and biopsy location. En, endothelial; Ep, epithelial; F, fibroblast; L, lymphocytes; Mc, mast cells; My, myeloid; P, pericytes; SMCs, smooth muscle cells; SMG, submucosal glands.

Supplemental Figure 4. Group-wise gene expression correlation for variable genes. A) UpSet plots showing differential gene expression at the single-cell level by epithelial compartment for SSc vs HCs (purple) and GERD vs HCs (orange) in the proximal and distal esophagus. **B)** Multidimensional scaling plots of aggregate gene expression samples colored by sample, epithelial compartment, condition, and biopsy location. **C-D)** Pseudobulk gene expression differences between SSc and HCs **(C)** and between SSc and GERD **(D)** are shown for each EEC compartment. Significant DEGs (FDR<0.05) are highlighted in purple and raspberry, respectively. The percentages of genes that were significantly differentially expressed in each compartment are plotted in blue in along the secondary Y axis. **E)** The number of significant DEGs are shown for GERD vs. HCs (orange) and for all permutations of n=4 samples for SSc vs. HCs (purple) in superficial cells for both proximal and distal regions. The point within the SSc distribution is the median value. **F-G)** The distributions of relative FC or slope m **(F)** and coefficient of determination r^2 **(G)** are shown for all permutations of n=4 SSc samples, determined by modeling a linear regression with intercept=0 for the $\log_2$FC of SSc vs. HCs against the $\log_2$FC of GERD vs. HCs for all expressed genes in the superficial compartment for both proximal and distal regions. DEG, differentially expressed gene; FC, fold change. **H)** Boxplots of pseudobulk gene expression, aggregated by condition, biopsy location, and EEC compartment for disease-specific DEGs referenced in the main text. Pairwise differential expression was determined using edgeR's quasi-likelihood F-tests: *p<0.05; **p<0.05; ***p<0.0005.

Supplemental Figure 5. Expression of cluster markers, enriched transcription factors, and their targets in superficial EECs in proximal esophagus. A) UMAPs with expression for the top superficial cluster markers are shown along with the epithelial differentiation score for superficial cells. **B-D)** The

1020   distributions of enriched transcription factor expression and target module scores are shown proximal,

1021   superficial cells by condition and superficial cluster for **B)** *IRF1*, **C)** *MYC*, **D)** *E2F4*, and **E)** *NE2L2*. **F)** Violin

1022   plots of gene expression in superficial cluster 5 vs. all other superficial subclusters for SSc-specific

1023   differentially expressed genes that were uniquely expressed in cluster 5 within superficial EECs.

1024

1025   **Supplemental Figure 6. *FLI1* expression in human esophageal mucosa. A)** UMAP of integrated

1026   mucosal dataset, colored by *FLI1* expression. The distribution of *FLI1* expression by cell type is shown in

1027   the upper right. **B)** Distribution of *FLI1* expression by cell type and disease state. Endothelial cells had the

1028   highest *FLI1* expression, but the expression differences between diseases was not significant. **C)** Violin

1029   plot of the relative expression of FLI1 target genes in superficial cells.

1030

Supplemental Figure 7. Epithelial cell compartment proportions and additional correlations by

motility phenotype. A-B) Proportions of esophageal epithelial cell compartments by HRM **(A)** and FLIP

(B) esophageal dysmotility phenotypes are shown for the proximal and distal esophagus samples. The

bars denote the mean values, the vertical lines the standard deviations, and the points the individual

sample proportions. **C)** The relationship between the proportion of superficial cells and the SSc disease

duration is plotted for proximal and distal samples. Trendlines with 95% confidence intervals are plotted in

pink, and correlation P-values are displayed in the upper right corners. **D)** The distribution of normalized

gene expression values by esophageal motility phenotype are shown for the *TRIM11* gene for the FLIP,

HRM, and NM esophageal dysmotility classifications. Unadjusted ordinal regression p-values are

displayed in the upper left corners. *TRIM11* was the most strongly association gene with the dysmotility

phenotypes by p-value. HRM, high-resolution manometry; FLIP, functional luminal imaging probe

panometry; IEM, ineffective esophageal motility; EGJOO, esophagogastric junction outflow obstruction;

NM, neuromyogenic model.

TABLES

Table 1. Sc-RNA-seq patient demographics and clinical characteristics

	HCs			SSc			GERD		
Demographics	**N = 6**			**N = 10**			**N = 4**		
Sex – female	5 (83.3%)			9 (90%)			3 (75%)		
Race – white	5 (83.3%)			8 (80%)			2 (50%)		
Ethnicity – non-Hispanic	5 (83.3%)			8 (80%)			2 (50%)		
Race/ethnicity – unknown/NR	1 (16.7%)			2 (20%)			2 (50%)		
Traits	N	**Median (IQR)**		N	**Median (IQR)**		N	**Median (IQR)**	
Age (yrs)	6	27 (25-29)		10	54 (47-70)		4	42 (30-56)	
BMI (kg/m^2)	6	23 (22-25)		10	22 (19-30)		4	24 (23-36)	
Esophageal motility									
Mean DCI (mmHg•s•cm)	6	464.2 (386-6-1026.1)		10	57.5 (0.0-206.1)		2	509.6 (367.4-651.7)	
Pressure 60ml (mmHg)	6	43.5 (38.3-54.5)		9	31.0 (30.5-40.3)		0	-	
EGJ barrier function									
End-expiratory EGJ pressure (mmHg)	6	7 (4-8)		10	6 (3-10)		2	12 (11-12)	
EGJ contractile index (mmHg•cm)	6	19.4 (15.2-29.0)		10	21.0 (19.1-27.5)		2	19.0 (10.8-27.1)	
Median IRP (mmHg)	6	4 (3-9)		10	6 (4-12)		2	8 (6-9)	
EGJ-DI (mm^2/mmHg)	6	6.2 (5.2-8.5)		9	6.3 (4.1-9.2)		-	-	
Reflux severity									
AET (%)	6	0.8 (0.5-2.8)		4	8.7 (3.3-14.5)		3	16.8 (13.9-17.3)	
GerdQ[118] score	6	0 (0-0)		10	3 (1-4)		3	3 (3-4)	
BEDQ[38] score	6	0 (0-0)		8	8 (3-14)		3	1 (1-1)	
NEQOL[39] score	6	56 (56-56)		8	31 (23-47)		3	36 (29-46)	

1045   AET, acid exposure time; BEDQ, brief esophageal dysphagia questionnaire; BMI, body mass index; DCI, distal contractile integral;

1046   DI, distensibility index; EGJ, esophagogastric junction; HCs, healthy controls; IQR, inter-quartile range; IRP, integrated relaxation

1047   pressure; NEQOL, Northwestern esophageal quality of life; NR, not reported; scRNA-seq, single-cell RNA sequencing.

1048